What are the causes of non-megaloblastic macrocytic hyperchromic anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Non-megaloblastic macrocytic hyperchromic anemia is primarily caused by conditions such as alcoholism, liver disease, hypothyroidism, reticulocytosis, and certain medications, and its management should focus on addressing the underlying condition rather than the anemia itself. The diagnosis of this condition involves a complete blood count showing elevated MCV (>100 fL) and MCHC, peripheral blood smear examination, and specific tests to determine the underlying cause such as liver function tests, thyroid panel, and medication review 1.

Causes and Diagnosis

The causes of non-megaloblastic macrocytic hyperchromic anemia can be identified through a thorough diagnostic approach, including:

  • Complete blood count (CBC) to determine MCV and MCHC levels
  • Peripheral blood smear examination to rule out other conditions
  • Liver function tests to assess for liver disease
  • Thyroid panel to evaluate for hypothyroidism
  • Medication review to identify potential offending drugs

Treatment and Management

Treatment of non-megaloblastic macrocytic hyperchromic anemia focuses on addressing the underlying condition, which may include:

  • Cessation of alcohol consumption for alcoholism
  • Hepatology referral for liver disease management
  • Levothyroxine replacement for hypothyroidism, typically starting at 25-50 mcg daily, adjusted based on TSH levels
  • Discontinuation of the offending drug if medication-induced
  • Nutritional support, particularly B-complex vitamins, regardless of the underlying cause

Prognosis

The prognosis for non-megaloblastic macrocytic hyperchromic anemia is generally favorable when the underlying condition is properly managed, with blood parameters typically normalizing within weeks to months of appropriate treatment 1. It is essential to prioritize the management of the underlying condition to improve morbidity, mortality, and quality of life outcomes for patients with this condition.

From the Research

Non Megaloblastic Macrocytic Hyperchromic Anemia

  • Non megaloblastic macrocytic anemia is a type of anemia characterized by large red blood cells, but without the presence of megaloblasts, which are large nucleated red blood cell precursors with uncondensed chromatin 2.
  • The causes of nonmegaloblastic macrocytic anemia include chronic liver dysfunction, hypothyroidism, alcohol use disorder, and myelodysplastic disorders 2, 3, 4.
  • Alcoholism is a common cause of nonmegaloblastic macrocytic anemia, and it can lead to macrocytosis, which is defined as a mean corpuscular volume (MCV) greater than 100 femtoliter (fL) 3, 4, 5.
  • Other causes of nonmegaloblastic macrocytic anemia include myelodysplastic syndrome (MDS), liver dysfunction, hypothyroidism, and certain drugs 4.
  • The diagnosis of nonmegaloblastic macrocytic anemia involves laboratory tests such as blood smear, vitamin B12 and red blood cell folate levels, reticulocyte count, and thyroid and liver function tests 3.
  • The treatment of nonmegaloblastic macrocytic anemia is specific to the underlying cause and may involve addressing the underlying condition, such as treating liver disease or hypothyroidism, or discontinuing certain medications 2, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Anemia: Macrocytic Anemia.

FP essentials, 2023

Research

Macrocytic anemia.

American family physician, 1996

Research

Diagnosis and treatment of macrocytic anemias in adults.

Journal of general and family medicine, 2017

Research

Macrocytosis in alcohol-related liver disease: its value for screening.

Clinical and laboratory haematology, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.